PubRank

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Clinical Trial ID NCT00450619

PubWeight™ 23.58‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00450619

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 133.74
2 Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011 2.20
3 Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012 2.09
4 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
5 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
6 Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001 1.52
7 The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012 1.44
8 A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991 1.22
9 Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 2012 1.16
10 Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011 1.12
11 Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals. Dalton Trans 2011 1.11
12 Viral vector-based therapeutic cancer vaccines. Cancer J 2011 1.00
13 Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012 0.93
14 A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 2011 0.92
15 Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A 2014 0.91
16 Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014 0.86
17 In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. Mol Cancer Ther 2012 0.84
18 The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer 2010 0.83
19 mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014 0.83
20 Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunol Res 2016 0.79
21 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
22 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
23 Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) 2013 0.76
24 Beyond Palliation: Therapeutic Applications of (153)Samarium-EDTMP. Clin Exp Pharmacol 2013 0.75
Next 100